Key result
Celastrol alleviates SGLT2i-induced hyperketonemia in mice by inhibiting hepatic ketogenesis via PPARα.
Supports further study of PPARα modulators to counter SGLT2 inhibitor ketosis; leaves open translation to patients.
mice. Importantly, celastrol effectively ameliorates SGLT2i-induced hyperketonemia. In summary, celastrol curbs hepatic ketone overproduction in a PPARα-dependent manner, indicating its protective potential against SGLT2i-induced hyperketonemia.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question. Celastrol alleviates SGLT2 inhibitor-induced hyperketonemia in mice by inhibiting hepatic ketogenesis through a PPARα-dependent mechanism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: